Cerenome, Inc. (CNSY) stock
CNSYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/3071% below fair value
$0.63−0.08 (-11.82%)
Close on Nov 17, 2026Market cap $4.78MP/E –Yield –
Cerenome total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Cerenome's total debt was $3.59M at Mar 31, 2024. For fiscal 2023 it was $3.98M, down 26.3% from the year before. Over ten years it grew -17.2% a year on average. The highest annual figure on record is $26.29M in fiscal 2013.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $3.98M | -26.3% |
| FY2022 | Dec 31, 2022 | $5.39M | -18.4% |
| FY2021 | Dec 31, 2021 | $6.61M | +4.4% |
| FY2020 | Dec 31, 2020 | $6.34M | -42.7% |
| FY2019 | Dec 31, 2019 | $11.06M | -22.1% |
| FY2018 | Dec 31, 2018 | $14.20M | +4.2% |
| FY2017 | Dec 31, 2017 | $13.62M | -22.8% |
| FY2016 | Dec 31, 2016 | $17.64M | +5.7% |
| FY2015 | Dec 31, 2015 | $16.68M | -34.3% |
| FY2014 | Dec 31, 2014 | $25.40M | -3.4% |
| FY2013 | Dec 31, 2013 | $26.29M | +15.9% |
| FY2012 | Dec 31, 2012 | $22.69M | -7.2% |
| FY2011 | Dec 31, 2011 | $24.45M | +24.1% |
| FY2010 | Dec 31, 2010 | $19.71M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2024 | Mar 31, 2024 | $3.59M | -29.0% |
| Q4 FY2023 | Dec 31, 2023 | $3.98M | -26.3% |
| Q3 FY2023 | Sep 30, 2023 | $4.35M | -23.9% |
| Q2 FY2023 | Jun 30, 2023 | $4.71M | -21.9% |
| Q1 FY2023 | Mar 31, 2023 | $5.06M | -20.1% |
| Q4 FY2022 | Dec 31, 2022 | $5.39M | -18.4% |
| Q3 FY2022 | Sep 30, 2022 | $5.72M | -15.3% |
| Q2 FY2022 | Jun 30, 2022 | $6.03M | -8.9% |
| Q1 FY2022 | Mar 31, 2022 | $6.33M | -2.5% |
| Q4 FY2021 | Dec 31, 2021 | $6.61M | +4.4% |
| Q3 FY2021 | Sep 30, 2021 | $6.75M | +9.2% |
| Q2 FY2021 | Jun 30, 2021 | $6.62M | +9.8% |
| Q1 FY2021 | Mar 31, 2021 | $6.49M | -42.0% |
| Q4 FY2020 | Dec 31, 2020 | $6.34M | -42.7% |
| Q3 FY2020 | Sep 30, 2020 | $6.18M | -43.5% |
| Q2 FY2020 | Jun 30, 2020 | $6.03M | -44.3% |
| Q1 FY2020 | Mar 31, 2020 | $11.18M | -22.2% |
| Q4 FY2019 | Dec 31, 2019 | $11.06M | -22.1% |
| Q3 FY2019 | Sep 30, 2019 | $10.94M | -21.9% |
| Q2 FY2019 | Jun 30, 2019 | $10.81M | -21.2% |
| Q1 FY2019 | Mar 31, 2019 | $14.37M | +5.5% |
| Q4 FY2018 | Dec 31, 2018 | $14.20M | +5.2% |
| Q3 FY2018 | Sep 30, 2018 | $14.01M | -3.5% |
| Q1 FY2018 | Mar 31, 2018 | $13.73M | -14.7% |
| Q4 FY2017 | Dec 31, 2017 | $13.62M | -22.8% |
| Q3 FY2017 | Sep 30, 2017 | $13.50M | -22.4% |
| Q2 FY2017 | Jun 30, 2017 | $14.52M | -15.4% |
| Q1 FY2017 | Mar 31, 2017 | $16.09M | – |
| Q4 FY2016 | Dec 31, 2016 | $17.64M | – |
| Q3 FY2016 | Sep 30, 2016 | $17.40M | – |
| Q2 FY2016 | Jun 30, 2016 | $17.16M | – |
See a number that looks wrong?